Peptide Comparison
PNC-27vsThymosin Alpha-1
A cancer-fighting peptide that works like a smart missile—it hunts down and destroys cancer cells by poking holes in them, while leaving your healthy cells completely untouched.
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
At a Glance
Quick
comparison
Dose Range
PNC-27
1–2 mg
Thymosin Alpha-1
1.6–3.2 mg
Frequency
PNC-27
Once daily
Thymosin Alpha-1
Twice weekly
Administration
PNC-27
Subcutaneous injection
Thymosin Alpha-1
Subcutaneous injection
Cycle Length
PNC-27
4-6 weeks
Thymosin Alpha-1
8-12 weeks
Onset Speed
PNC-27
Rapid (hours to days)
Thymosin Alpha-1
Moderate (1-2 weeks)
Evidence Level
PNC-27
Strong preclinical (extensive animal studies)
Thymosin Alpha-1
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Cancer Cell Selectivity
Rapid Action
Broad Spectrum
Immune Activation
Infection Fighting
Immune Balance
Technical Data
Compound
specifications
PNC-27
Molecular Formula
C188H293N53O44S
Molecular Weight
4031.73 g/mol
Half-Life
2-4 hours (estimated from preclinical data)
Bioavailability
High when injected subcutaneously
CAS Number
1159861-00-3
Thymosin Alpha-1
Molecular Formula
C129H215N33O55
Molecular Weight
3108.32 g/mol
Half-Life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS Number
62304-98-7
Protocols
Dosing
tiers
PNC-27
Thymosin Alpha-1
Applications
Best
suited for
PNC-27
Solid Tumor Research
PNC-27 has shown remarkable results against solid tumors in lab studies. It's been tested against breast, pancreatic, colon, and ovarian cancer cells—and in each case, it killed the cancer cells while the healthy cells next to them stayed perfectly fine. That's the holy grail of cancer research.
Leukemia and Blood Cancer Studies
In studies on acute myeloid leukemia (AML), PNC-27 wiped out cancer cells within just 4 hours. It works on several types of leukemia cells (U937, OCI-AML3, HL-60) by targeting a protein that only shows up on cancer cell surfaces. Normal blood cells? Completely unharmed.
Cancer Stem Cell Targeting
Here's where PNC-27 gets really interesting: it can kill cancer stem cells. These are the sneaky cells that often survive chemo and cause cancer to come back. PNC-27 has shown it can destroy CD44+ colon cancer stem cells, which is a big deal for preventing recurrence.
Drug-Resistant Cancer Research
When cancers stop responding to regular chemotherapy, researchers need new approaches. PNC-27 works through a completely different mechanism than traditional chemo drugs, so it may be effective against cancers that have become resistant to other treatments.
Thymosin Alpha-1
Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.
Safety Profile
Side
effects
PNC-27
Common
- Injection site redness
- Mild fatigue
- Localized warmth or tenderness
Uncommon
- Headache
- Low-grade fever
Serious
- Allergic reaction
Thymosin Alpha-1
Common
- Injection site reactions
- Mild fatigue
- Flu-like symptoms
Uncommon
- Mild fever
- Lymph node awareness
Serious
- Allergic reaction
Research Status
Safety
& evidence
PNC-27
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
Here's the really cool thing about PNC-27: in all the lab and animal studies so far, it ONLY attacks cancer cells. Normal, healthy cells are completely ignored because they don't have the protein (HDM-2) on their surface that PNC-27 targets. Animal studies using doses up to 40 mg/kg showed tumors shrinking or disappearing with zero damage to normal tissues. That said, it hasn't been tested in human clinical trials yet, so we're still learning.
Contraindications
- xPregnancy or planning to become pregnant
- xCurrently breastfeeding
- xKnown allergy to peptide components
- xSevere immune system disorders without specialist guidance
Thymosin Alpha-1
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for other use
Safety Overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.
Contraindications
- xOrgan transplant recipients on immunosuppressants
- xActive autoimmune disease flares
- xKnown allergy to thymosin peptides
- xPregnancy or breastfeeding
- xChildren under 18 without medical supervision
Decision Guide
Which is
right for you?
Choose PNC-27 if...
- Cancer research protocols
- Oncology support research
- Targeting treatment-resistant cancers
- Cancer stem cell research
Choose Thymosin Alpha-1 if...
- Immune system strengthening
- Chronic infection support
- Cancer adjunct therapy
- Healthy aging immune support